Table 1 The cost (Euros) of grade 3–4 (grade 2) adverse event management per patient for bevacizumab plus IFN and sunitinib in patients with metastatic RCC in the United Kingdom, Germany, France and Italy

From: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

	United Kingdom			Germany			France			Italy
		Percent cost			Percent cost			Percent cost			Percent cost
Adverse event	Cost per event ^a	Sunitinib	Bevacizumab + IFN	Cost per event ^a	Sunitinib	Bevacizumab + IFN	Cost per event ^a	Sunitinib	Bevacizumab + IFN	Cost per event ^b	Sunitinib	Bevacizumab + IFN
Anaemia	2494 (112)	7.4	6.3	2194 (45)	5.3	4.6	1557 (3924)	23.4	11.6	1323	5.9	10.0
Anorexia	70 (70)	0	1.9	1860 (45)	0	4.5	36 (1911)	0	3.5	—	—	—
ATE	2494 (112)	0	1.7	2988^c (74)	0	1.7	523 (3592)	0	1.8	—	—	—
Bleeding	637 (637)	0	16.1	2376 (88)	0	6.2	79 (3592)	0	6.7	291	0	2.2
Chills	42 (42)	0.1	0	2946 (65)	1.5	0	78 (2236)	0.5	0	—	—	—
Decline eject fraction	1123 (1123)	1.3	0	2427 (65)	2.5	0	67 (4158)	1.7	0	1773	3.9	0
Depression	224 (224)	0	2.0	1860 (65)	0	4.1	147 (2072)	0	3.9	—	—	—
Diarrhoea	3207 (112)	9.1	6.4	1245 (45)	3.7	2.1	41 (2471)	2.8	2.9	1995	11.2	10.0
Dry skin	0 (112)	0	0	0 (45)	0.2	0	0	0	0	—	—	—
Dyspnoea	42 (42)	0	0.4	1269 (45)	0	0.8	78 (2236)	0	1.2	—	—	—
Epistaxis	1084 (112)	1.0	0	1209 (45)	0.8	0	32 (1328)	0.3	0	—	—	—
Fatigue/asthaenia	372 (372)	10.8	18.5	1860 (45)	10.7	28.6	36 (1911)	4.5	22.3	307	3.8	16.9
GI perforation	5929 (112)	0	4.5	16 929^c (0)	0	8.1	36 (8263)	0	4.2	5926	0	14.6
Hair colour changes	70 (70)	0.4	0	0 (45)	0.2	0	0	0	0	—	—	—
HFS	2589 (112)	6.2	0	2304 (45)	5.8	0	35 (881)	1.0	0	310	1.8	0
Headache	274 (274)	0.1	0.4	1527 (45)	0.9	2.5	32 (1217)	0.3	1.6	—	—	—
Heart failure	3293 (112)	0	0.8	5271^c (74)	0	0.9	67 (4158)	0	0.6	1773	0	1.2
Hypertension	21 (21)	0.2	0.4	1509 (45)	6.1	3.6	150 (2614)	4.5	5.8	1773	15.9	13.1
Influenza-like syndrome	42 (42)	0	0.8	3567 (45)	0	5.3	78 (2236)	0	4.3	—	—	—
Leucopaenia	1792 (112)	7.3	0	2376 (88)	7.9	0	498 (4432)	11.4	0	1802	10.1	0
Lymphopaenia	1792 (1792)	11.4	0	2376 (88)	15.2	0	498 (4432)	15.0	0	1802	24.2	0
Mucosal inflammation	495 (495)	4.2	0	1713 (45)	1.9	0	33 (33)	0.1	0	310	0.7	0
Myalgia	274 (274)	0.6	0	1623 (45)	0.8	0	0	0	0	—	—	—
Nausea	2803 (112)	5.5	0	1245 (45)	2.4	0	73 (602)	0.9	0	375	1.2	0
Neutropaenia	1792 (70)	12.0	5.7	2376 (88)	15.6	6.6	498 (4432)	16.2	9.8	511	6.8	5.0
Pain extremity	274 (274)	0.6	0	1623 (45)	0.9	0	35 (881)	0.2	0	—	—	—
Proteinuria	3929 (112)	0	22.0	1446 (87)	0	7.3	106 (2131)	0	8.2	137	0	2.5
Pyrexia	42 (42)	0.1	1.4	2946 (65)	1.6	5.3	78 (2236)	0.5	4.0	—	—	—
Rash	148 (148)	1.2	0	513 (45)	0.8	0	31 (1257)	0.6	0	310	0.7	0
Skin discolouration	70 (70)	0.5	0	0 (45)	0.2	0	31 (1257)	0.1	0	—	—	—
Stomatitis	495 (88)	1.1	0	1614 (65)	1.3	0	31 (2360)	0.6	0	—	—	—
Thrombocytopaenia	3372 (112)	13.2	5.4	2376 (0)	10.9	3.4	75 (3852)	14.4	5.5	1323	11.9	6.5
VTE	2246 (112)	0	5.1	2988^c (74)	0	3.5	74 (1305)	0	1.4	3591	0	17.9
Vomiting	2803 (112)	5.5	0	1245 (45)	2.7	0	73 (602)	0.8	0	375	1.7	0
Wound healing complications	148 (148)	0	0.1	3696 (77)	0	1.1	32 (2360)	0	0.7	—	—	—

Abbreviations: ATE=arterial thromboembolic events; GI=gastrointestinal; HFS=hand-foot syndrome; IFN=interferon-α2a; VTE=venous thromboembolic events.
^aGrade 2 costs are shown in parentheses.
^bGrade 3–4 costs only.
^cGrade 3 cost lower than grade 4, grade 4 cost listed.

Back to article page

Table 1 The cost (Euros) of grade 3–4 (grade 2) adverse event management per patient for bevacizumab plus IFN and sunitinib in patients with metastatic RCC in the United Kingdom, Germany, France and Italy

Search

Quick links